Arbutus Biopharma (ABUS) announced its 2025 corporate objectives and provided a financial update. The Company had cash, cash equivalents and investments in marketable securities totaling ...
Arbutus Biopharma (ABUS – Research Report), the Healthcare sector company, was revisited by a Wall Street analyst today. Analyst Ed Arce from H.C. Wainwright maintained a Buy rating on the stock ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback